EVOKE/EVOKE+

Investigating Semaglutide in People with Early Alzheimer’s Disease

The EVOKE trial is a clinical study designed to investigate whether oral semaglutide can be an effective treatment for individuals with early Alzheimer’s disease. Semaglutide has shown promise in earlier studies for reducing inflammation in the brain and slowing down the progression of cognitive decline (memory and thinking problems). Oral semaglutide is semaglutide that comes in tablet form, rather than an injection.
The main goal of the EVOKE trial is to compare the effects of oral semaglutide with a placebo in improving memory and thinking, and daily functioning in people with mild cognitive impairment or mild Alzheimer’s disease dementia. The study will also check if the medication is safe and well-tolerated by participants.
Additionally, the trial will look at the way semaglutide affects brain function, inflammation, and heart health. The study will recruit participants from around the world and follow them for up to three years.
If the results of the EVOKE trial show that oral semaglutide can help reduce cognitive decline and improve symptoms for people with mild Alzheimer’s disease dementia, it could become a new treatment option for those living with the disease.
The EVOKE and EVOKE Plus trials are similar, but are considered separate studies as people who also have cerebral vascular changes (heart conditions) will take part in the EVOKE Plus trial, instead.